Forte Biosciences (FBRX) Research & Development (2016 - 2026)

Forte Biosciences (FBRX) has reported Research & Development for 11 consecutive years, with $20.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 62.02% year-over-year to $20.3 million; the TTM figure through Mar 2026 stood at $65.4 million (up 126.13% YoY), while the FY2025 annual figure was $57.6 million, up 178.3% from the prior year.
• Research & Development eased to $20.3 million in Q1 2026 per FBRX's latest filing, from $21.6 million in the prior quarter.
• Across five years, Research & Development topped out at $21.6 million in Q4 2025 and bottomed at $693000.0 in Q1 2022.
• Historically, Research & Development has averaged $7.4 million across 5 years, with a median of $5.6 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development slumped 79.14% — and 2023, when it soared 590.76%.
• Forte Biosciences' Research & Development stood at $2.5 million in 2022, then soared by 43.37% to $3.6 million in 2023, then soared by 42.42% to $5.1 million in 2024, then surged by 324.92% to $21.6 million in 2025, then slipped by 5.86% to $20.3 million in 2026.
• Business Quant data shows FBRX's Research & Development at $20.3 million in Q1 2026, $21.6 million in Q4 2025, and $15.0 million in Q3 2025.